Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03859765
Other study ID # Pro00100321
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 23, 2019
Est. completion date December 20, 2021

Study information

Verified date September 2022
Source Duke University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Hematopoietic stem cell transplant (HCT) is an aggressive treatment for life-threatening cancers. HCT improves survival, but most HCT patients experience significant physical disability, which is exacerbated by persistent symptoms. Pain, fatigue, and psychological distress are the most prevalent and debilitating symptoms. HCT patients experience a significant increase in disability as their pain, fatigue, and distress increase. This disability and symptom burden interferes with patients' ability to engage in recommended physical activity that can improve disability, symptoms, and other outcomes. Disability and symptoms also complicate an already challenging recovery course; HCT patients return home, often far from their medical team, are restricted from normal activities and socially isolated. These disability, symptom and activity challenges increase the risk for post-transplant complications and may compromise life expectancy. Teaching HCT patients to cope with symptoms and activity is critical to helping them increase activity and reduce disability. Cognitive behavioral coping skills training protocols can enhance HCT patients' ability to cope with symptoms (pain, fatigue, distress) that interfere with physical activity. However, the application of these protocols to HCT patients is limited by in person sessions, delivery of sessions in a medical center setting, and/or lack of tailoring to HCT patients' specific needs. Mobile health (mHealth) technologies can improve and extend intervention strategies to cope with symptoms and physical activity upon return home. Behavioral intervention strategies are needed to enable HCT patients to effectively cope with symptoms to improve their ability to engage in physical activity that can improve physical disability. The investigators aim to develop and test a combined coping skills training and activity coaching protocol that: first, is feasible and acceptable, and second, improves physical disability, as well as pain, fatigue, distress, and physical activity in HCT patients. Specifically, the investigators will develop and test an in-person and mHealth HCT Coping Skills Training for Symptom Management and Daily Steps (HCT Symptoms and Steps) intervention protocol. To do this, the investigators will develop a mobile app, conduct focus groups, complete user testing, and conduct a small randomized controlled trial (RCT) to examine feasibility, acceptability, and outcome patterns suggesting intervention efficacy of the developed HCT Symptoms and Steps protocol. Following the development phase of the study (i.e., focus groups), the investigators will conduct user testing with 10 cancer patients who have undergone HCT; all 10 patients will receive the HCT Symptoms and Steps intervention. Next, the investigators will randomly assign 40 cancer participants who have undergone HCT and report pain, fatigue and stress to receive either HCT Symptoms and Steps or HCT Education. The investigators will test whether HCT Symptoms and Steps is feasible and acceptable to HCT patients, and improves physical disability, as well as other important outcomes. The investigators expect that HCT Symptoms and Steps will be feasible and acceptable to HCT patients and, compared to HCT Education, will be more likely to lead to improvements in physical disability, as well as pain, fatigue, distress, physical activity, and self-efficacy for symptom management. The investigators' goal is to demonstrate the feasibility, acceptability, and positive impact of a hybrid in-person and mHealth coping skills training and activity coaching intervention that reduces physical disability by concurrently and synergistically decreasing symptom burden and increasing physical activity. This project has the potential to lead to future research that can redesign existing modes of behavioral intervention delivery, improve continuity and coordination of care, and ultimately enhance patient outcomes.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date December 20, 2021
Est. primary completion date December 20, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Hematopoietic stem cell transplant due to oncological disease - Clinical ratings of pain, fatigue and psychological distress - Life expectancy of 12 or more months Exclusion Criteria: - Cognitive impairment - Severe psychiatric condition - Inability to converse in English

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
HCT Symptoms and Steps
HCT Symptoms and Steps will provide patients with cognitive behavioral coping skills training and activity coaching sessions to enhance their ability to manage symptoms that interfere with activity.

Locations

Country Name City State
United States Duke Cancer Institute Durham North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Duke University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility as Measured by Number of Participants Accrued to the Study Within 16 Months Feasibility will be shown by meeting targeted study accrual (N=40) in the 16-month study period. 16 months (additional year granted due to COVID-19).
Primary Number of Participants Who Adhere to at Least 80% of the Study Protocol A measure of feasibility. approximately 20-24 weeks
Primary Number of Participants Who do Not Complete the 3-month Post-treatment Follow-up Assessment A measure of feasibility. approximately 20-24 weeks
Primary Acceptability as Measured by the Client Satisfaction Questionnaire (CSQ) 8-item Version This questionnaire contains 8 items rated from 1=low acceptability to 4=high acceptability; scores are created by utilizing the Likert Scale to sum CSQ answers resulting in a score range from 8 to 32. The intervention is considered acceptable if the mean value for acceptability across all participants is above 80% of max acceptability score (i.e., 25.6). post-treatment (approximately 7-12 weeks)
Secondary Change in Physical Disability as Measured by the the Functional Assessment of Cancer Therapy (FACT) Physical Disability will be assessed using the Functional Assessment of Cancer Therapy 7-item physical well-being scale. Each item is scored 0=not at all to 4=very much as the statement applies to the past 7 days. The full range of the scale is 0 to 28, with a higher score indicating a better outcome. pre-treatment (baseline), post-treatment (approximately 7-12 weeks)
Secondary Change in Pain Severity Pain severity will be assessed with the Brief Pain Inventory (BPI). Patients will rate their "pain right now", "worst", "least" and "average" pain in the last week from 0=no pain to 10=worst pain imaginable. An average of the responses to these items is used to create a single pain severity score. pre-treatment (baseline), post-treatment (approximately 7-12 weeks).
Secondary Change in Fatigue Fatigue will be assessed using the Patient Reported Outcomes Measurement Information System (PROMIS) seven-item Fatigue Scale. For each item, the statement applies to the past 7 days: "never" (1), "rarely" (2), "sometimes" (3), "often" (4), or "always" (5). The summed score is then converted to a T-Score (0-100), where a higher T-Score indicates worse fatigue. 50 indicates the population mean with a standard deviation of 10. 50 and below is considered below average, 50-60 is mild, and 60 or greater is moderate/severe. pre-treatment (baseline), post-treatment (approximately 7-12 weeks).
Secondary Change in Physical Activity Physical Activity will be assessed via step count with a wireless activity tracker (e.g., Fitbit). A distinct value pre and post treatment are reported, no averages were taken across multiple days. pre-treatment (baseline), post-treatment (approximately 7-12 weeks).
Secondary Change in Depression Depression will be assessed using the Hospital Anxiety and Depression Scale (HADS). Each question rated 0-3, totaling 21 points.Total score of 0-7 = normal, 8-10 = borderline abnormal, 11-21 = abnormal. pre-treatment (baseline), post-treatment (approximately 7-12 weeks)
Secondary Change in Anxiety. Anxiety will be assessed using the Hospital Anxiety and Depression Scale (HADS). Each question rated 0-3, totaling 21 points.Total score of 0-7 = normal, 8-10 = borderline abnormal, 11-21 = abnormal. pre-treatment (baseline), post-treatment (approximately 7-12 weeks)
Secondary Change in Self-Efficacy Change in self-efficacy as measured by the Self-Efficacy for Symptom Management scale: 1=not at all confident to 10=totally confident. pre-treatment (baseline), post-treatment (approximately 7-12 weeks)
See also
  Status Clinical Trial Phase
Completed NCT03641378 - Inpatient Palliative Care for Patients Undergoing Hematopoietic Stem Cell Transplantation N/A
Recruiting NCT06155188 - Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia N/A
Recruiting NCT03562065 - Treatment of Refractory Systemic Lupus Erythematosus by Allogeneic Mesenchymal Stem Cells Derived From the Umbilical Cord Phase 1/Phase 2
Completed NCT01468935 - Bone Marrow Cell Engraftment of the Uterus and Genetic Studies of Reproductive Functioning
Active, not recruiting NCT03938324 - Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults With Chronic Conditions N/A
Completed NCT04219657 - Comparison Between Skin Graft Versus Skin Graft and Stem Cell Application Phase 1
Not yet recruiting NCT03259217 - Clinical Application of Mesenchymal Stem Cells Seeded in Chitosan Scaffold for Diabetic Foot Ulcers Phase 1
Recruiting NCT01189786 - Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection N/A
Recruiting NCT04610359 - Safety of Human Embryonic Stem Cell (hESC)-Derived Mesenchymal Stem Cells in Interstitial Cystitis Phase 1
Completed NCT05712148 - Spheroidal Mesenchymal Stem Cells in Retinitis Pigmentosa Phase 1/Phase 2
Recruiting NCT05515497 - BMT4me: Post-HSCT Medication Adherence mHealth App N/A
Completed NCT01984671 - Mobile Pain Coping Skills Training for Stem Cell Transplant Patients N/A
Not yet recruiting NCT06075927 - Multivirus-specific T Cells in the Treatment of Refractory CMV and/or EBV Infection After Allo-HSCT Phase 1/Phase 2
Completed NCT03440775 - Digital Stories and Psychosocial Wellbeing in Stem Cell Transplant Patients N/A
Recruiting NCT02652052 - Hematopoietic Stem Cell Transplant Survivors Study N/A
Not yet recruiting NCT04922970 - Strength Training as Prevention and Treatment of Late Effects in Long-term Survivors of Pediatric HSCT. N/A
Completed NCT01092195 - Gardasil Vaccination in Post Stem Cell Transplant Patients Phase 1
Completed NCT04041219 - Use of Sublingual Tacrolimus in Adult Blood and Marrow Transplant Patients Phase 4
Completed NCT00656058 - Montelukast to Treat Bronchiolitis Obliterans Phase 2
Recruiting NCT04375579 - Assessment of Elderly Undergoing Allogeneic Hematopoietic Stem Cell Transplantation